Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Zelira Therapeutics ( (AU:ZLD) ) just unveiled an announcement.
Zelira Therapeutics has announced significant progress in its diabetic neuropathy study, with its proprietary cannabinoid-based therapy, ZLT-L-007, outperforming Lyrica® in reducing pain and improving quality of life for patients. This advancement, alongside the conversion of US$3.25 million in convertible notes into equity, strengthens Zelira’s financial position and supports its clinical and regulatory development efforts. The company is poised to continue its momentum with upcoming FDA trials and the optimization of its Zyraydi™ technology, aiming to unlock value across its product lines.
More about Zelira Therapeutics
Zelira Therapeutics Ltd is a global leader in the development and commercialization of clinically validated cannabinoid-based medicines. The company focuses on creating therapies that address various medical conditions, leveraging its expertise in cannabinoid science to offer innovative solutions across multiple therapeutic verticals and geographies.
Average Trading Volume: 4,920
Technical Sentiment Signal: Sell
Current Market Cap: A$4.88M
See more insights into ZLD stock on TipRanks’ Stock Analysis page.